Sana Biotechnology, Inc.
SANA
$1.76
-$0.01-0.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.04M | 67.55M | 72.68M | 72.80M | 73.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 271.47M | 296.76M | 296.00M | 353.65M | 326.90M |
| Operating Income | -271.47M | -296.76M | -296.00M | -353.65M | -326.90M |
| Income Before Tax | -266.76M | -305.81M | -244.90M | -308.61M | -283.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -266.76 | -305.81 | -244.90 | -308.61 | -283.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -266.76M | -305.81M | -244.90M | -308.61M | -283.26M |
| EBIT | -271.47M | -296.76M | -296.00M | -353.65M | -326.90M |
| EBITDA | -255.97M | -280.81M | -279.61M | -336.71M | -309.36M |
| EPS Basic | -1.17 | -1.41 | -1.15 | -1.53 | -1.46 |
| Normalized Basic EPS | -0.72 | -0.83 | -0.86 | -1.06 | -1.02 |
| EPS Diluted | -1.17 | -1.41 | -1.15 | -1.53 | -1.46 |
| Normalized Diluted EPS | -0.72 | -0.83 | -0.85 | -1.06 | -1.02 |
| Average Basic Shares Outstanding | 923.44M | 884.46M | 846.03M | 804.13M | 778.06M |
| Average Diluted Shares Outstanding | 923.44M | 884.46M | 849.52M | 807.62M | 781.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |